Horizon says it is the right time to add inhouse manufacturing capabilities as it acquires a facility from EirGen Pharma. Horizon Therapeutics will pay OPKO health’s EirGen Pharma $65 million for the 44,000 square-foot drug product manufacturing facility located in Waterford, Ireland. The facility includes a filling line, lyophiliser or freeze dryer, which can be used for the firm’s commercial medicines such as Tepezza (teprotumumab-trbw), Krystexxa and Uplizna (inebilizumab-cdon) plus other drugs in its pipeline. The successful launch of Tepezza,…

CDMO Genezen will build a lentiviral vector manufacturing facility to support clients and early-stage clinical trials. Gene therapy contract development manufacturing organization (CDMO) Genezen Laboratories will construct a 75,000+ square-foot lentiviral vector production facility in Indianapolis, US. The investment contributes to Genezen’s lentiviral and retroviral vector production, which enables the CDMO to support current and future clients to supply early phase clinical trials. “Lentiviral vectors are the leading platform for in-vitro gene therapy, representing over 35% of the clinical trial market and it…

AbCellera will build a manufacturing facility in Vancouver, Canada to prepare for future pandemics and advance their own clinical pipeline. The 130,000 square-foot Vancouver facility will produce therapeutic antibodies making it the first of its kind in Canada. The facility will not be used to support any COVID-19 related products. However, in-country manufacturing of antibodies is “important for Canada because it fills a major gap in our ability as a nation to respond to future pandemics,” Murray McCutcheon, vice president,…

Vor Biopharma plans to build a cell therapy manufacturing facility to make supplies for clinical trials. The facility – at Vor’s Cambridge, Massachusetts headquarters – will make hematopoietic stem cell and chimeric antigen receptor T-cell (CAR-T) candidates for trials. Construction is expected to complete in 2022. According to Vor, positioning all its production processes under one roof will reduce production costs and accelerate timelines. The firm told BioProcess Insider: “By integrating its internal research, process development, analytical development, manufacturing, and…

CDMO Jubilant HollisterStier will supply Indian COVID-19 vaccine Covaxin from its sterile injectable site in Spokane, Washington, currently undergoing a capacity expansion. Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is a highly purified and inactivated vaccine manufactured using a vero cell manufacturing platform. Philadelphia-based biotech Ocugen is working with Bharat to bring the vaccine in Canada and the US and has selected contract development and manufacturing organization (CDMO) Jubilant HollisterStier to help…